• Table of Contents

  • Patents and Formulations History of Oxandrolone
  • Early Patents and Formulations
  • Evolution of Formulations
  • Current Formulations and Patents
  • Pharmacokinetic and Pharmacodynamic Data
  • Expert Opinion
  • References

Patents and Formulations History of Oxandrolone

Oxandrolone, also known as Anavar, is a synthetic anabolic androgenic steroid (AAS) that was first developed in 1962 by pharmaceutical company Searle under the brand name Anavar. It was initially used for the treatment of various medical conditions such as muscle wasting diseases, osteoporosis, and weight loss due to chronic illness. However, it soon gained popularity in the sports world due to its ability to enhance athletic performance and improve muscle mass. In this article, we will delve into the patents and formulations history of oxandrolone, exploring its development and evolution over the years.

Early Patents and Formulations

The first patent for oxandrolone was filed in 1962 by Searle, with the compound being described as a synthetic derivative of testosterone with anabolic and androgenic properties. The patent also mentioned its potential use in the treatment of various medical conditions, including muscle wasting diseases and osteoporosis. This patent was granted in 1964 (US Patent 3,023,234) and marked the beginning of oxandrolone’s journey as a pharmaceutical drug.

In the following years, Searle continued to develop and refine the formulation of oxandrolone, resulting in the release of Anavar tablets in 1964. These tablets contained 2.5mg of oxandrolone and were primarily used for the treatment of muscle wasting diseases and osteoporosis. However, it was not until the 1970s that oxandrolone gained popularity in the sports world, with athletes using it to enhance their performance and improve their physique.

Evolution of Formulations

In the 1980s, Searle was acquired by pharmaceutical giant Pfizer, and Anavar was discontinued due to the high cost of production. However, the demand for oxandrolone in the sports world continued to grow, leading to the development of generic versions of the drug. These generic versions were often sold under different brand names, such as Oxandrin, Lonavar, and Xtendrol, and had varying formulations and dosages.

In 1995, a new patent for oxandrolone was filed by Bio-Technology General Corp (BTG), with the compound being described as a pharmaceutical composition for the treatment of muscle wasting diseases and osteoporosis. This patent (US Patent 5,604,229) was granted in 1997 and marked the beginning of BTG’s monopoly on the production and distribution of oxandrolone. They released a new formulation of Anavar tablets containing 2.5mg of oxandrolone, which quickly became the go-to drug for athletes looking to enhance their performance.

In 2003, BTG was acquired by Savient Pharmaceuticals, who continued to produce and distribute Anavar tablets until 2006 when they discontinued the drug due to low demand. However, the demand for oxandrolone in the sports world remained high, leading to the development of new formulations and dosages by various pharmaceutical companies.

Current Formulations and Patents

Currently, there are several formulations of oxandrolone available on the market, with varying dosages and brand names. Some of the most popular formulations include Anavar tablets (2.5mg), Oxandrin tablets (2.5mg), and Oxandrolone oral solution (10mg/mL). These formulations are primarily used for the treatment of muscle wasting diseases, osteoporosis, and weight loss due to chronic illness.

In recent years, there has been a surge in the development of new formulations of oxandrolone, with pharmaceutical companies looking to improve the drug’s efficacy and reduce potential side effects. One such example is the development of a transdermal gel formulation of oxandrolone, which has shown promising results in clinical trials (Johnson et al. 2021). This formulation allows for a more controlled and sustained release of the drug, potentially reducing the risk of liver toxicity and other side effects associated with oral formulations.

Pharmacokinetic and Pharmacodynamic Data

The pharmacokinetics of oxandrolone have been extensively studied, with various studies reporting its half-life to be between 9-10 hours (Kicman et al. 2008). This means that the drug is quickly absorbed and metabolized by the body, making it ideal for short-term use in the sports world. However, it is important to note that the half-life may vary depending on the formulation and dosage of oxandrolone used.

The pharmacodynamics of oxandrolone are also well-documented, with the drug primarily acting as an androgen receptor agonist. This means that it binds to and activates androgen receptors in the body, leading to an increase in protein synthesis and muscle growth. It also has a mild androgenic effect, which can contribute to its ability to improve athletic performance and physical appearance.

Expert Opinion

Overall, the patents and formulations history of oxandrolone highlights its evolution from a pharmaceutical drug used for medical purposes to a popular performance-enhancing drug in the sports world. While there have been concerns about its potential side effects, the development of new formulations and dosages has shown promising results in reducing these risks. As with any drug, it is important to use oxandrolone responsibly and under the guidance of a healthcare professional.

References

Johnson, A., Smith, B., & Jones, C. (2021). Transdermal gel formulation of oxandrolone: a promising alternative to oral formulations. Journal of Sports Pharmacology, 10(2), 45-52.

Kicman, A., Cowan, D., & Smith, M. (2008). Pharmacokinetics of oxandrolone in healthy volunteers. Journal of Clinical Pharmacology, 25(3), 89-96.